Siggy launches a continuous-care model for psychiatry built around daily data and clinician oversight
Siggy entered the market with a simple claim and an ambitious clinical premise: mental health care should not stop at a 15-minute visit. The platform is designed to collect a patient’s story once, preserve it in memory, and then keep building on it through daily check-ins, wearable data, and ongoing conversations between visits. Every treatment decision remains under the control of licensed clinicians, but the system is built to surface changes early enough to influence medication choices, tapering decisions, and follow-up intensity before a patient slides into crisis.
A one-minute check-in may sound modest. In psychiatry, it can be the difference between catching a deteriorating pattern and discovering it only after a missed refill, a sleepless stretch, or a full relapse.
The launch arrives against a stark backdrop. More than 54 million American adults had a mental illness last year, and nearly half received no treatment. Another 137 million live in designated mental health professional shortage areas, where only about 27% of need is met. In that setting, medication is often prescribed outside specialty psychiatry, visits can be months apart, and many patients stop treatment within the first three months. Siggy’s model is built to intervene in the long gaps between appointments, when symptoms, adherence, and side effects usually unfold out of sight.
Daily symptom tracking becomes a single score clinicians can follow
At the center of the platform is the Siggy Score, a number from 0 to 100 that patients and clinicians see every day. The score is built from four daily questions on sleep, mood, medication, and how the body feels, plus data from connected devices such as Apple Watch, Oura, or Whoop. Wearable integration is not cosmetic here. Sleep fragmentation, altered activity, and physiologic strain often precede obvious psychiatric decline, especially in anxiety, depression, and trauma-related illness, so a widening gap between a patient’s usual pattern and current data can reveal trouble before the next office visit ever arrives.
Patients begin with a free, anonymous conversation and no account or login. Siggy remembers that first exchange and keeps expanding on it with every later interaction, with the aim of preventing patients from repeating the same history each time they encounter a new clinician. For people who have bounced between providers, that continuity could reduce the friction that often leads to disengagement. It also creates a longitudinal record that is more clinically useful than a single intake form, because psychiatric symptoms rarely sit still long enough to be captured in one interview.
Pattern detection is built to pull clinicians in before a crisis develops
Siggy is not positioned as a standalone chatbot or a substitute prescriber. When the system detects a pattern building over several days, it flags the change to the patient’s clinician with the context behind it. The model depends on licensed clinicians making every diagnosis, prescription, and treatment decision, and the company says weekly check-ins through the first two months allow clinicians to decide within days whether to hold a dose, increase it, or switch medication. That kind of cadence may matter most when treatment is just getting started, because early tolerability problems and incomplete response often determine whether a patient stays engaged long enough to improve.
The platform also gives patients a place to talk between visits. Instead of responding only to a single isolated message, Siggy draws on the full history it has stored, including prior conversations and check-in data. In practical terms, that is the clinical difference between a generic reassurance and a response shaped by what has actually happened over time. A patient who says, “I’m so tired of feeling this anxious” is not just sending a sentence into a void; the system is meant to compare that statement with prior sleep disruption, past medication changes, and earlier symptom trends before deciding whether the clinician needs to know.
A treatment model built around goals, not just prescriptions
Siggy also asks patients to define the outcomes they care about, such as sleeping through the night or eating dinner with family once a month. Those goals are then tracked over time, which gives treatment a functional target instead of reducing it to symptom scores alone. In psychiatry, that distinction matters because symptom reduction and real-world recovery do not always move together. A patient can report fewer panic attacks and still be unable to work, socialize, or tolerate ordinary routines.
Medication is presented as one tool among several. Clinicians can taper patients off when they are ready, which suggests the platform is intended for longitudinal management rather than indefinite drug maintenance by default. That approach fits a broader shift in mental health care toward measuring change continuously rather than assuming that a prescription written months ago is still the right answer today. It also reflects a simple bedside truth: psychiatric treatment works best when it is adjusted to the person in front of the clinician, not to the version of that person remembered from the last visit.
Founder experience, clinical design, and investor backing shape the launch
Jonathan Sabbagh, Siggy’s co-founder and CEO, built the company after a long personal and professional arc through burnout, trauma recovery, and care that finally worked. He spent 20 years in finance before being diagnosed with PTSD tied to childhood trauma, later studied psychology, and went on to build Journey Clinical, a psychedelic-assisted therapy network that he says grew into the largest in the United States, with more than 3,000 practices and over one million hours of supervised care. Edvard Engesaeth, MD, now chief operating officer, co-founded Nurx and helped scale it past two million patients and a $100 million run rate.
The leadership team also includes Jake Bourke as chief technology officer and Daniel Montville, MD, as chief medical officer. The company says its medical team includes clinicians trained at Yale School of Medicine, the University of Chicago, and Mercy University.
Siggy is backed by $6 million in pre-seed funding led by Village Global. Repeat backers include Albert Wenger of Union Square Ventures, Immad Akhund of Mercury, Toyin Ajayi of Cityblock Health through Coalition Operators, Psymed Ventures, Christina Sass of Andela, Andrew Parker of Papa, Steven Gutentag and Demetri Karagas of Thirty Madison and Nurx, Daft VC, Mystic Ventures, and several angels.
Insurance access could determine whether the model reaches scale
Coverage may prove as important as the software itself. Siggy says it is covered by most insurance plans in all 50 states, including Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Humana, and that it reaches roughly 80% of insured Americans. HSA and FSA payments are accepted, and the service is free for veterans permanently. Those details matter because digital psychiatry tools often stall when access is limited to patients who can pay out of pocket. A system built around continuous monitoring only has a real chance to change care if patients can stay in it long enough for the data to become meaningful.
The remaining question is not whether daily tracking is possible. It is whether a platform that combines memory, wearables, and clinician oversight can actually improve adherence, reduce symptom escalation, and keep patients in treatment over time while preserving the judgment of the licensed clinician at the center of care.